GLP-1 Drugs Like Ozempic Linked to Lower Dementia Risk in New Studies

Recent research highlights a significant reduction in Alzheimer's and dementia risk for type 2 diabetes patients using GLP-1 receptor agonists, while emphasizing the need for further trials.

Two studies published in JAMA Neurology found that GLP-1 receptor agonists, such as Ozempic and Wegovy, are associated with a lower risk of dementia in type 2 diabetes patients.
A meta-analysis of 26 trials involving over 160,000 participants showed GLP-1 drugs reduced dementia risk by approximately 45%, while evidence for SGLT2 inhibitors remains mixed.
Researchers suggest the neuroprotective effects of GLP-1 drugs may stem from reduced inflammation and improved cardiovascular health, beyond their blood sugar control benefits.
The findings are limited to type 2 diabetes patients, with experts calling for large-scale trials to explore potential benefits for non-diabetic populations and confirm long-term effects.
While promising, the studies underscore the need for further research to establish the safety and efficacy of GLP-1 drugs for dementia prevention.